The trial will also evaluate the effect of the drug on glucose and insulin resistance.
Rhythm chief development officer Liz Stoner said the Phase 2 study is expected to expand the understanding of RM-493’s profile for the treatment of obesity.
"Based on the data from preclinical studies and early clinical trials, we believe RM-493 has substantial therapeutic potential for reducing body weight and insulin resistance in obese and diabetic patients," Stoner added.
RM-493 is a small-peptide melanocortin 4 receptor (MC4R) agonist that is being developed for the treatment of obesity and diabetes.